106 related articles for article (PubMed ID: 11337186)
21. Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae.
Bogdanovich T; Bozdogan B; Appelbaum PC
Antimicrob Agents Chemother; 2006 Mar; 50(3):893-8. PubMed ID: 16495248
[TBL] [Abstract][Full Text] [Related]
22. In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes.
De Vecchi E; Nicola L; Zucchetti E; Drago L
J Chemother; 2006 Aug; 18(4):379-88. PubMed ID: 17024793
[TBL] [Abstract][Full Text] [Related]
23. Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
Nagai K; Davies TA; Ednie LM; Bryskier A; Palavecino E; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2001 Nov; 45(11):3242-5. PubMed ID: 11600391
[TBL] [Abstract][Full Text] [Related]
24. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Pontani D; Washton H; Bouchillon S; Johnson J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
[TBL] [Abstract][Full Text] [Related]
26. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance.
Burgess DS; Hastings RW; Horan JL
Ann Pharmacother; 1999 Dec; 33(12):1262-5. PubMed ID: 10630825
[TBL] [Abstract][Full Text] [Related]
27. Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides.
Wierzbowski AK; Boyd D; Mulvey M; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2005 Nov; 49(11):4635-40. PubMed ID: 16251306
[TBL] [Abstract][Full Text] [Related]
28. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.
Kosowska K; Credito K; Pankuch GA; Hoellman D; Lin G; Clark C; Dewasse B; McGhee P; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4113-9. PubMed ID: 15504829
[TBL] [Abstract][Full Text] [Related]
29. Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.
Metzler K; Drlica K; Blondeau JM
J Antimicrob Chemother; 2013 Mar; 68(3):631-5. PubMed ID: 23169894
[TBL] [Abstract][Full Text] [Related]
30. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data.
Carbon C; Poole MD
J Chemother; 1999 Apr; 11(2):107-18. PubMed ID: 10326741
[TBL] [Abstract][Full Text] [Related]
31. [Antibacterial activity of clarithromycin and its hydroxylated derivative and two other macrolides against thirty strains of Streptococcus pneumoniae].
Ploy MC; Mounier M; Denis F
Pathol Biol (Paris); 1994 May; 42(5):379-84. PubMed ID: 7824300
[TBL] [Abstract][Full Text] [Related]
32. Macrolide resistance among middle ear isolates of Streptococcus pneumoniae observed at eight United States pediatric centers: prevalence of M and MLSB phenotypes.
Mason EO; Wald ER; Bradley JS; Barson WJ; Kaplan SL;
Pediatr Infect Dis J; 2003 Jul; 22(7):623-7. PubMed ID: 12867838
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro.
Van Asselt GJ; Sloos JH; Mouton RP; Van Boven CP; Van de Klundert JA
J Med Microbiol; 1995 Nov; 43(5):386-91. PubMed ID: 7563004
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of clarithromycin against penicillin-susceptible and penicillin-resistant strains of Streptococcus pneumoniae in a pharmacodynamic simulation model.
Fuentes F; Sevillano D; Balcabao IP; Gómez-Lus ML; Prieto J
J Chemother; 2000 Dec; 12(6):495-8. PubMed ID: 11154032
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal macrolide resistance--myth or reality?
Amsden GW
J Antimicrob Chemother; 1999 Jul; 44(1):1-6. PubMed ID: 10459803
[TBL] [Abstract][Full Text] [Related]
36. In vitro comparative dynamics of modified-release clarithromycin and of azithromycin.
Scaglione F; Demartini G; Dugnani S; Fraschini F
Chemotherapy; 2000; 46(5):342-52. PubMed ID: 10965100
[TBL] [Abstract][Full Text] [Related]
37. [Macrolide-resistant Streptococcus pneumoniae in the pediatric population in Beijing].
Yang H; Shen XZ; Wang YH; Yuan L; Yu SJ; Yang YH
Zhonghua Er Ke Za Zhi; 2004 Dec; 42(12):936-9. PubMed ID: 15733368
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin.
Zhang L; Song L; Liu Z; Li H; Lu Y; Li Z; Ma S
Eur J Med Chem; 2010 Mar; 45(3):915-22. PubMed ID: 19945195
[TBL] [Abstract][Full Text] [Related]
40. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus.
Maurer FP; Castelberg C; Quiblier C; Böttger EC; Somoskövi A
J Antimicrob Chemother; 2014 Jun; 69(6):1559-63. PubMed ID: 24500188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
